KLRK1 and ovarian carcinoma: Ultimately, Barber and colleagues suggested that their findings indicate that T cells endowed with NKG2D-based chimeric receptors are potential therapeutic options for ovarian cancer; however, broader investigation at the clinical level is warranted for such assertions (122).